NAYA Biosciences Inc

NASDAQ:NAYAUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

NAYA Biosciences, Inc. formerly INVO Bioscience, Inc. operates the fertility business, as well as its focus to the development of clinical-stage assets in oncology and autoimmune diseases. The Company’s initial pipeline includes two novel Flex-NK Bispecific Antibodies. NY-303: its GPC3-targeted FLEX-NK Bispecific Antibody for Hepatocellular Carcinoma (HCC). NY-338: its CD38-targeted FLEX-NK Bispecific Antibody for Multiple Myeloma (MM) & Autoimmune Diseases. Its lead GPC3-targeting FLEX-NK bispecific antibody is entering Phase I/II clinical trials and positioned as a monotherapy option to address the unmet needs of the of hepatocellular carcinoma (HCC) patients not responding to standard of care with checkpoint inhibitors. INVOcell is its novel, FDA-cleared and CE-marked intravaginal culture (IVC) device. It offers a viable alternative to vitro fertilization (IVF) that uses the female body for fertilization and incubation, keeping women at the center of the reproductive process.

Contact Information

Headquarters

5582 Broadcast CourtSARASOTA, FL, United States 34240

Phone

978-878-9505

Fax

---

Executives

President, Director

Daniel Teper

Chief Executive Officer, Director

Steven Shum

Chief Financial Officer

Andrea Goren

Chief Operating Officer, Vice President - Business Development

Michael Campbell

Director

Lyn Falconio